{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T22:09:15Z","timestamp":1779401355518,"version":"3.53.1"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","license":[{"start":{"date-parts":[[2023,3,3]],"date-time":"2023-03-03T00:00:00Z","timestamp":1677801600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,3,3]]},"abstract":"<jats:p>To analyze the incidence and nongenetic risk factors of irinotecan-induced severe neutropenia in the hospital, and provide additional reference and help for clinical treatment. A retrospective analysis of patients who received irinotecan based chemotherapy from May 2014 to May 2019 in Renmin Hospital of Wuhan University was conducted. Univariate analysis and binary logistic regression analysis with the forward stepwise method were used to assess the risk factors associated with severe neutropenia induced by irinotecan. Of the 1312 patients treated with irinotecan-based regmines, only 612 patients met the inclusion criteria, and 32 patients developed irinotecan-induced severe neutropenia. In the univariate analysis, variables associated with severe neutropenia were tumor type, tumor stage, and therapeutic regimen. In the multivariate analysis, irinotecan plus lobaplatin, lung cancer or ovarian cancer, tumor stage T<jats:sub>2<\/jats:sub>, T<jats:sub>3<\/jats:sub>, and T<jats:sub>4<\/jats:sub>, were identified as risk factors that contributed independently to irinotecan-induced severe neutropenia (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; .05), respectively. The results showed that the incidence of irinotecan\u2013induced severe neutropenia was 5.23% in the hospital. The risk factors included tumor type (lung cancer or ovarian cancer), tumor stage (T<jats:sub>2<\/jats:sub>, T<jats:sub>3<\/jats:sub>, and T<jats:sub>4<\/jats:sub>) and therapeutic regimen (irinotecan plus lobaplatin). Therefore, for patients with these risk factors, it might be advisable to actively consider optimum management to reduce the occurrence of irinotecan\u2013induced severe neutropenia.<\/jats:p>","DOI":"10.1097\/md.0000000000033005","type":"journal-article","created":{"date-parts":[[2023,3,2]],"date-time":"2023-03-02T20:04:00Z","timestamp":1677787440000},"page":"e33005","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Incidence and non-genetic risk factors of irinotecan-induced severe neutropenia in Chinese adult inpatients"],"prefix":"10.1097","volume":"102","author":[{"given":"Shuxiao","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Renmin Hospital of Wuhan University, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JingXiang","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Wuhan Children\u2019s Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Zhan","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Wuhan Jinyintan Hospital, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boning","family":"Yang","sequence":"additional","affiliation":[{"name":"Sydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"PeiPei","family":"Rong","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Renmin Hospital of Wuhan University, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Renmin Hospital of Wuhan University, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cai","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Renmin Hospital of Wuhan University, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Renmin Hospital of Wuhan University, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9734-8588","authenticated-orcid":false,"given":"Jian","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Renmin Hospital of Wuhan University, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1179\/1973947812Y.0000000020","article-title":"The efficacy and toxicity of irinotecan with leucovorin and bolus and continuous infusional 5-fluorouracil (FOLFIRI) as salvage therapy for patients with advanced gastric cancer previously treated with platinum and taxane based chemotherapy regimens.","volume":"24","author":"Kaya","year":"2012","journal-title":"J Chemother"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1179\/joc.2011.23.6.358","article-title":"FOLFIRI chemotherapy in patients with advanced non resectable esophageal or junctional adenocarcinoma: a pilot study.","volume":"23","author":"Ferte","year":"2011","journal-title":"J Chemother"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJM200009283431302","article-title":"Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan study group.","volume":"343","author":"Saltz","year":"2000","journal-title":"N Engl J Med"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1200\/JCO.2004.07.173","article-title":"Genetic variants in the UDP glucuronosyl transferase 1A1 gene predict the risk of severe neutropenia of irinotecan.","volume":"22","author":"Innocenti","year":"2004","journal-title":"J Clin Oncol"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/tpj.2015.23","article-title":"Clinical validity of new genetic biomarkers of irinotecan neutropenia: an independent replication study.","volume":"16","author":"Crona","year":"2016","journal-title":"Pharmacogenomics J"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.2217\/14622416.7.8.1211","article-title":"Pharmacogenetics of irinotecan: clinical perspectives on the utility of genotyping.","volume":"7","author":"Innocenti","year":"2006","journal-title":"Pharmacogenomics"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/sj.bjc.6602042","article-title":"MUGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer.","volume":"91","author":"Marcuello","year":"2004","journal-title":"Br J Cancer"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"5151","DOI":"10.1158\/1078-0432.CCR-03-0548","article-title":"Relevance of different UGT1A1 polymorphisms in irinotecan induced toxicity: a molecular and clinical study of 75 patients.","volume":"10","author":"Rouits","year":"2004","journal-title":"Clin Cancer Res"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.ctrv.2008.05.002","article-title":"Clinical and pharmacogenetic factors associated with irinotecan toxicity.","volume":"34","author":"Kweekel","year":"2008","journal-title":"Cancer Treat Rev"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1002\/cncr.23370","article-title":"UGT1A1*28 polymorphism predicts irinotecan induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma.","volume":"112","author":"Liu","year":"2008","journal-title":"Cancer"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1038\/bjc.2015.122","article-title":"An internally and externally validated nomogram for predicting the risk ofirinotecan induced severe neutropenia in advanced colorectal cancer patients.","volume":"112","author":"Ichikawa","year":"2015","journal-title":"B J Cancer"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.critrevonc.2013.12.006","article-title":"Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: a systematic review.","volume":"90","author":"Lyman","year":"2014","journal-title":"Crit Rev Oncol Hematol"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.critrevonc.2019.03.016","article-title":"Neutropenia during frontline treat-ment of advanced Hodgkin lymphoma: incidence, risk factors, and management.","volume":"138","author":"Sureda","year":"2019","journal-title":"Crit Rev Oncol Hemato"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s12032-019-1288-7","article-title":"High total bilirubin level is a significant risk factor for severe neutropenia in patients receiving irinotecan based chemotherapy.","volume":"36","author":"Yamada","year":"2019","journal-title":"Med Oncol"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1007\/s12032-013-0604-x","article-title":"UGT1A1*6\/*28 polymorphisms could predict irinotecan induced severe neutropenia not diarrhea in Chinese colorectal cancer patients.","volume":"30","author":"Gao","year":"2013","journal-title":"Med Oncol"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"111346","DOI":"10.18632\/oncotarget.22795","article-title":"A multicenter prospective phase II study of frst-line modifed FOLFIRINOX for unresectable advanced pancreatic cancer.","volume":"8","author":"Yoshida","year":"2017","journal-title":"Oncotarget"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"15574","DOI":"10.1038\/s41598-022-18669-9","article-title":"Incidence of and risk factors for severe neutropenia during treatment with the modifed FOLFIRINOX therapy in patients with advanced pancreatic cancer.","volume":"12","author":"Irisawa","year":"2022","journal-title":"Sci Rep"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1007\/s12032-013-0630-8","article-title":"Associations between UGT1A1*6\/*28 polymorphisms and irinotecan induced severe toxicity in Chinese gastric or esophageal cancer patients.","volume":"30","author":"Gao","year":"2013","journal-title":"Med Oncol"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1200\/JCO.1997.15.1.251","article-title":"Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy naive patients and patients pretreated with fluorouracil based chemotherapy.","volume":"15","author":"Rougier","year":"1997","journal-title":"J Clin Oncol"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1038\/sj.bjc.6601214","article-title":"Irinotecan plus leucovorin modulated 5-fluorouracil I.V. bolus every other week may be a suitable therapeutic option also for elderly patients with metastatic colorectal carcinoma.","volume":"89","author":"Comella","year":"2003","journal-title":"Br J Cancer"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s00280-004-0915-x","article-title":"A phase I, dose finding study of irinotecan (CPT-11) short i.v. infusion combined with fixed dose of 5-fluorouracil (5-FU) protracted i.v. infusion in adult patients with advanced solid tumours.","volume":"55","author":"Sastre","year":"2005","journal-title":"Cancer Chemother Pharmacol"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1159\/000089992","article-title":"Combination of irinotecan (CPT-11) plus 5-fluorouracil and leucovorin (FOLFIRI regimen) as first line treatment for elderly patients with metastatic colorectal cancer: a phase II trial.","volume":"69","author":"Souglakos","year":"2005","journal-title":"Oncology (Huntingt)"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1002\/(SICI)1097-0142(19990215)85:4<786::AID-CNCR5>3.0.CO;2-9","article-title":"A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma.","volume":"85","author":"Rothenberg","year":"1999","journal-title":"Cancer"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1200\/JCO.1997.15.4.1502","article-title":"Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients.","volume":"15","author":"Gupta","year":"1997","journal-title":"J Clin Oncol"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1200\/JCO.2006.09.6115","article-title":"Cigarette smoking and irinotecan treatment: pharmacokinetic interaction and effects on neutropenia.","volume":"25","author":"Van der Bol","year":"2007","journal-title":"J Clin Oncol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000033005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T02:35:56Z","timestamp":1746326156000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000033005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,3]]},"references-count":25,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000033005","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3,3]]}}}